Bristol-Myers Squibb Company / Repare Therapeutics Inc.

Solid Tumors (DDR Synthetic Lethality Precision Oncology)

250 US cases/yr · $160.0B Global oncology therapeutics market 2020 · ~$3.07B Total deal BD value (up to, incl. milestones + equity)

Disease Overview

The BMS-Repare partnership targets solid tumors carrying DNA damage response (DDR) defects, leveraging synthetic lethality to selectively kill tumor cells. The addressable population spans tumors harboring BRCA1/2, ATM, ATR, ARID1A, MTAP, RAD51 paralog, and other DDR-pathway mutations and deletions across breast, ovarian, prostate, pancreatic, and colorectal cancers — collectively accounting for an estimated 250,000-400,000 U.S. patients per year with actionable DDR alterations. The synthetic lethality concept, first commercialized via PARP inhibitors in BRCA-mutant breast and ovarian cancer, has expanded to second-generation targets including Werner helicase (WRN, synthetic lethal with MSI-high), PKMYT1 (synthetic lethal with CCNE1 amplification), Polθ (synthetic lethal with HR-deficient tumors), and USP1 (synthetic lethal with BRCA mutation). PARP inhibitor revenue (Lynparza, Zejula, Rubraca, Talzenna) reached approximately $4.5B globally in 2020, providing the commercial template. Repare's SNIPRx CRISPR-based functional genomics platform identifies novel synthetic lethal pairs across the cancer genome and feeds the BMS collaboration. WAC pricing for branded targeted oncology agents in DDR-defined populations ranges $14K-20K per month.

Competitive Landscape

The DDR synthetic lethality competitive landscape is one of the most contested precision oncology spaces. PARP inhibitors set the franchise template — Lynparza/olaparib (AstraZeneca/Merck), Zejula/niraparib (GSK), Rubraca/rucaparib (Pharma&), and Talzenna/talazoparib (Pfizer) — combined revenue of approximately $4.5B in 2020. Next-generation DDR programs include ATR inhibitors (camonsertib/RP-3500 Repare, ceralasertib AstraZeneca, elimusertib Bayer), ATM inhibitors (M3541 Merck KGaA), WEE1 inhibitors (adavosertib AstraZeneca, debio 0123 Debiopharm), Polθ inhibitors (RP-6306/PKMYT1 Repare, novobiocin), USP1 inhibitors (KSQ-4279 KSQ Therapeutics), and Werner helicase inhibitors (vactosertib Vivace, IDE275 Ideaya). The BMS deal acquires options across multiple SNIPRx-identified targets in addition to the lead Repare program (RP-3500/camonsertib in ATM-mutant solid tumors). Tango Therapeutics (Gilead partner), Boundless Bio, and Cyteir offer competing CRISPR-functional-genomics platforms. The deal positions BMS-Repare against AstraZeneca-Merck's Lynparza-anchored DDR franchise.